PRIMA BIOMED
Live / Registered — Cancelled — Section 71 (as of 01 Mar 2024)
What this means for you
Registered since 15 Aug 2017. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79191113
- Registration number
- 5262954
- Mark type
- Stylized text
- Filed
- 06 May 2016
- Published for opposition
- 30 May 2017
- Registered
- 15 Aug 2017
- Attorney of record
- Edward Playfair
Goods and services
- Class 001 — Chemicals: Chemical reactants and reagents for scientific and laboratory use; chemicals for use in industry and science; antibodies and recombinant proteins for use in laboratories and for scientific purposes
- Class 005 — Pharmaceuticals: Pharmaceutical and veterinary preparations for the treatment of cancer and autoimmune diseases [ ; ] *, * reactants and reagents for medical diagnostic purposes; diagnostic preparations and reagents for medical purposes; antibodies and recombinant proteins for use in medical applications, namely, adjuvants for the treatment of cancer and autoimmune diseases * ; none of the aforementioned being for use by lactating and pregnant women *
Owner
- Immutep Limited, AU
- Prima Biomed Ltd, AU
- Prima Biomed Ltd, AU
Prosecution history
- 21 Dec 2024 — TOTAL INVALIDATION PROCESSED BY THE IB
- 30 Nov 2024 — TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
- 29 Nov 2024 — INVALIDATION PROCESSED
- 02 Nov 2024 — TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
- 01 Mar 2024 — CANCELLED SECTION 71
- 12 Oct 2022 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 12 Oct 2022 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 12 Oct 2022 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 12 Oct 2022 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 12 Oct 2022 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 15 Aug 2022 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 27 Aug 2018 — INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
- 05 Aug 2018 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 02 Feb 2018 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 22 Dec 2017 — FINAL DECISION TRANSACTION PROCESSED BY IB